Tiziana Life Sciences (TLSA) Non-Current Debt (2020)
Tiziana Life Sciences (TLSA) posted quarterly Non-Current Debt of $324000.0 for Q4 2020.
Tiziana Life Sciences (TLSA) Non-Current Debt (2020) Analysis & Trends
Tiziana Life Sciences (TLSA) has reported Non-Current Debt for 1 consecutive years, with $324000.0 the latest figure, recorded in Q4 2020.
- Quarterly Non-Current Debt changed N/A year-over-year to $324000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $324000.0 (changed N/A YoY) and the FY2020 annual result came in at $324000.0, changed N/A from the prior year.
- Non-Current Debt held at $324000.0 in Q4 2020 per TLSA's latest filing.
- Over the last five years, Non-Current Debt for TLSA reached as high as $324000.0 in Q4 2020 and fell as low as $324000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 105.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 842.92 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Tiziana Life Sciences | 109.20 Mn | 105.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 324,000.00 |